Shinobi Therapeutics Secures $59M Grant from the Japanese Agency for Medical Research and Development

[cafead]

via

• Funds will support the development of Shinobi's lead iPS-T cell program targeting GPC3+ tumors.
• Shinobi also expands its investor syndicate, with the addition of Yosemite and Mitsubishi UFJ Capital, bringing the company's total funding to $119M.

article source